Improving Vascular Maturation Using Noncoding RNAs Increases Antitumor Effect of Chemotherapy

Overview

Journal JCI Insight

Specialties Biomedical Engineering
General Medicine

Date 2016 Oct 26

PMID 27777972

Citations 12

Authors

Lingegowda S Mangala

Hongyu Wang

Dahai Jiang

Sherry Y Wu

Anoma Somasunderam

David E Volk

Ganesh L R Lokesh

Xin Li

Sunila Pradeep

Xianbin Yang

Monika Haemmerle

Cristian Rodriguez-Aguayo

Archana S Nagaraja

Rajesha Rupaimoole

Emine Bayraktar

Recep Bayraktar

Li Li

Takemi Tanaka

Wei Hu

Cristina Ivan

Kshipra M Gharpure

Michael H McGuire

Varatharasa Thiviyanathan

Xinna Zhang

Sourindra N Maiti

Nataliya Bulayeva

Hyun-Jin Choi

Piotr L Dorniak

Laurence Jn Cooper

Kevin P Rosenblatt

Gabriel Lopez-Berestein

David G Gorenstein

Anil K Sood

Affiliations

Soon will be listed here.

Abstract

Current antiangiogenesis therapy relies on inhibiting newly developed immature tumor blood vessels and starving tumor cells. This strategy has shown transient and modest efficacy. Here, we report a better approach to target cancer-associated endothelial cells (ECs), reverse permeability and leakiness of tumor blood vessels, and improve delivery of chemotherapeutic agents to the tumor. First, we identified deregulated microRNAs (miRs) from patient-derived cancer-associated ECs. Silencing these miRs led to decreased vascular permeability and increased maturation of blood vessels. Next, we screened a thioaptamer (TA) library to identify TAs selective for tumor-associated ECs. An annexin A2-targeted TA was identified and used for delivery of miR106b-5p and miR30c-5p inhibitors, resulting in vascular maturation and antitumor effects without inducing hypoxia. These findings could have implications for improving vascular-targeted therapy.

Citing Articles

MicroRNA-155 and its exosomal form: Small pieces in the gastrointestinal cancers puzzle.

Guo J, Zhong L, Momeni M Cell Biol Toxicol. 2024; 40(1):77.

PMID: 39283408 PMC: 11405467. DOI: 10.1007/s10565-024-09920-2.

Liposomal Phenylephrine Nanoparticles Enhance the Antitumor Activity of Intratumoral Chemotherapy in a Preclinical Model of Melanoma.

Gabriel E, Bahr D, Rachamala H, Madamsetty V, Shreeder B, Bagaria S ACS Biomater Sci Eng. 2024; 10(5):3412-3424.

PMID: 38613483 PMC: 11301277. DOI: 10.1021/acsbiomaterials.4c00078.

Human intravital microscopy in the study of sarcomas: an early trial of feasibility.

Gabriel E, Sukniam K, Popp K, Bagaria S Front Oncol. 2023; 13:1151255.

PMID: 37124504 PMC: 10130404. DOI: 10.3389/fonc.2023.1151255.

miRNA therapeutics in precision oncology: a natural premium to nurture.

Jain C, Srivastava P, Pandey A, Singh N, Kumar R Explor Target Antitumor Ther. 2022; 3(4):511-532.

PMID: 36071981 PMC: 9446160. DOI: 10.37349/etat.2022.00098.

The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies.

El-Daly S, Bayraktar R, Anfossi S, Calin G Int J Mol Sci. 2020; 21(9).

PMID: 32403283 PMC: 7246984. DOI: 10.3390/ijms21093387.

References

Carey M, Peterson C, Smale S . Chromatin immunoprecipitation (ChIP). Cold Spring Harb Protoc. 2010; 2009(9):pdb.prot5279. DOI: 10.1101/pdb.prot5279. View

McGuire T, Sajithlal G, Lu J, Nicholls R, Prochownik E . In vivo evolution of tumor-derived endothelial cells. PLoS One. 2012; 7(5):e37138. PMC: 3356387. DOI: 10.1371/journal.pone.0037138. View

Lupold S, Hicke B, Lin Y, Coffey D . Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002; 62(14):4029-33. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Sennino B, McDonald D . Controlling escape from angiogenesis inhibitors. Nat Rev Cancer. 2012; 12(10):699-709. PMC: 3969886. DOI: 10.1038/nrc3366. View

Mann A, Somasunderam A, Nieves-Alicea R, Li X, Hu A, Sood A . Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One. 2010; 5(9). PMC: 2948018. DOI: 10.1371/journal.pone.0013050. View

Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P . Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem. 2007; 79(13):4900-7. DOI: 10.1021/ac070189y. View

Brownstein C, Deora A, Jacovina A, Weintraub R, Gertler M, Khan K . Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood. 2003; 103(1):317-24. DOI: 10.1182/blood-2003-04-1304. View

Zighelboim I, Wright J, Gao F, Case A, Massad L, Mutch D . Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013; 130(1):64-8. PMC: 3870479. DOI: 10.1016/j.ygyno.2013.04.009. View

10.

Wu S, Rupaimoole R, Shen F, Pradeep S, Pecot C, Ivan C . A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016; 7:11169. PMC: 4822037. DOI: 10.1038/ncomms11169. View

11.

Rosenberg J, Bambury R, Van Allen E, Drabkin H, Lara Jr P, Harzstark A . A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2013; 32(1):178-87. PMC: 4560460. DOI: 10.1007/s10637-013-0045-6. View

12.

Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, Tan W . Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol Cell Proteomics. 2007; 6(12):2230-8. DOI: 10.1074/mcp.M700026-MCP200. View

13.

Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S . Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer. J Nucl Med. 2013; 55(1):107-14. DOI: 10.2967/jnumed.113.125476. View

14.

Rupaimoole R, Wu S, Pradeep S, Ivan C, Pecot C, Gharpure K . Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014; 5:5202. PMC: 4215647. DOI: 10.1038/ncomms6202. View

15.

Millner R, Lockhart A, Bird H, Alexiou C . A new hemostatic agent: initial life-saving experience with Celox (chitosan) in cardiothoracic surgery. Ann Thorac Surg. 2009; 87(2):e13-4. DOI: 10.1016/j.athoracsur.2008.09.046. View

16.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

17.

Chakravarthy U, Adamis A, Cunningham Jr E, Goldbaum M, Guyer D, Katz B . Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006; 113(9):1508.e1-25. DOI: 10.1016/j.ophtha.2006.02.064. View

18.

Ferrara N, Hillan K, Gerber H, Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3(5):391-400. DOI: 10.1038/nrd1381. View

19.

Dua P, Kang H, Hong S, Tsao M, Kim S, Lee D . Alkaline phosphatase ALPPL-2 is a novel pancreatic carcinoma-associated protein. Cancer Res. 2013; 73(6):1934-45. DOI: 10.1158/0008-5472.CAN-12-3682. View

20.

Cataland S, Peyvandi F, Mannucci P, Lammle B, Kremer Hovinga J, Machin S . Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012; 87(4):430-2. DOI: 10.1002/ajh.23106. View